KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Q3 2025 value amounting to $129.8 million.

  • Supernus Pharmaceuticals' Short-term Investments fell 6506.7% to $129.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.8 million, marking a year-over-year decrease of 6506.7%. This contributed to the annual value of $384.3 million for FY2024, which is 11370.31% up from last year.
  • Supernus Pharmaceuticals' Short-term Investments amounted to $129.8 million in Q3 2025, which was down 6506.7% from $377.9 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Short-term Investments high stood at $384.3 million for Q4 2024, and its period low was $105.2 million during Q3 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' median Short-term Investments value was $196.5 million (recorded in 2022), while the average stood at $233.8 million.
  • In the last 5 years, Supernus Pharmaceuticals' Short-term Investments skyrocketed by 25315.86% in 2024 and then tumbled by 6506.7% in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Short-term Investments (Quarter) stood at $136.2 million in 2021, then surged by 170.26% to $368.2 million in 2022, then tumbled by 51.16% to $179.8 million in 2023, then skyrocketed by 113.7% to $384.3 million in 2024, then plummeted by 66.23% to $129.8 million in 2025.
  • Its last three reported values are $129.8 million in Q3 2025, $377.9 million for Q2 2025, and $347.7 million during Q1 2025.